Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inga T Lennes

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Contemporary Clinical Trials|October 4, 2021
Integrating tobacco treatment into lung cancer screening practices: Study protocol for the Screen ASSIST randomized clinical trialJordan M Neil, Caylin Marotta, Irina Gonzalez, et al.
JCO Precision Oncology|August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung CancerZofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
JTO Clinical and Research Reports|November 18, 2020
Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic ConsiderationsAndrew J Piper-Vallillo, Meghan J Mooradian, Catherine B Meador, et al.
JCO Precision Oncology|October 30, 2018
Clinical Utility of Rapid <i>EGFR</i> Genotyping in Advanced Lung CancerIbiayi Dagogo-Jack, Christopher G Azzolli, Florian Fintelmann, et al.
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 11, 2018
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in OncologyDouglas E Wood, Ella A Kazerooni, Scott L Baum, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2013
Thymomas and thymic carcinomas: Clinical Practice Guidelines in OncologyDavid S Ettinger, Gregory J Riely, Wallace Akerley, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 8, 2013
Non-small cell lung cancer, version 2.2013David S Ettinger, Wallace Akerley, Hossein Borghaei, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2022
NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022Douglas E Wood, Ella A Kazerooni, Denise Aberle, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Contemporary Clinical Trials|October 4, 2021
Integrating tobacco treatment into lung cancer screening practices: Study protocol for the Screen ASSIST randomized clinical trialJordan M Neil, Caylin Marotta, Irina Gonzalez, et al.
JCO Precision Oncology|August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung CancerZofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
JTO Clinical and Research Reports|November 18, 2020
Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic ConsiderationsAndrew J Piper-Vallillo, Meghan J Mooradian, Catherine B Meador, et al.
JCO Precision Oncology|October 30, 2018
Clinical Utility of Rapid <i>EGFR</i> Genotyping in Advanced Lung CancerIbiayi Dagogo-Jack, Christopher G Azzolli, Florian Fintelmann, et al.
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 11, 2018
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in OncologyDouglas E Wood, Ella A Kazerooni, Scott L Baum, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2013
Thymomas and thymic carcinomas: Clinical Practice Guidelines in OncologyDavid S Ettinger, Gregory J Riely, Wallace Akerley, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 8, 2013
Non-small cell lung cancer, version 2.2013David S Ettinger, Wallace Akerley, Hossein Borghaei, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2022
NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022Douglas E Wood, Ella A Kazerooni, Denise Aberle, et al.
Pageof 7